Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent prior to the performance of any protocol-specified procedure or, if unable to provide informed consent due to cognitive status, provides assent to participate, with a legally authorized representative (LAR) providing written informed consent on behalf of the participant.~2. 60 years of age or older~3. Meets core clinical criteria for probable AD dementia according to the 2011 National Institute on Aging-Alzheimer's Associated guidelines. Can be based on medical history.~4. Mini-Mental State Examination (MMSE) score of 20 to 26 (inclusive)~5. Confirmation of AD pathophysiology~6. At least 2 cardiovascular risk factors per protocol criteria~7. Magnetic resonance imaging (MRI) scan (existing MRI obtained ≤6 months before Screening is acceptable) findings of mild-to-moderate subcortical small-vessel disease~8. If receiving concomitant or chronic medication(s), has had no change for ≥4 weeks before study drug initiation and has no plans to alter the regimen(s) during the study~9. If male, agrees to refrain from donating sperm from the Screening visit through 90 days after taking the final study drug dose~10. If male, agrees to use protocol-specified, effective contraception methods from the signing of the informed consent form (ICF) until ≥90 days after taking the final study drug dose.~11. If female, is postmenopausal/not of reproductive potential defined per protocol~12. Agrees to the study procedures, including undergoing lumbar puncture for cerebrospinal fluid (CSF) samples~Exclusion Criteria:~1. Severe visual, auditory, social, or cognitive impairment~2. Dementia-related disorder other than AD or vascular dementia (eg, Parkinson's disease, Huntington's disease, frontotemporal dementia, schizophrenia, Lewy body dementia)~3. Symptomatic large-vessel disease, symptomatic carotid artery disease, large vessel infarcts, or strategic lacunar infarcts or infarcts\>15 mm~4. History of significant central nervous system (CNS) trauma that has affected brain function~5. Low blood pressure (BP), defined as systolic BP ≤90 mmHg or diastolic BP ≤60 mmHg.~6. Orthostatic hypotension.~7. Unable to undergo MRI~8. Unable to undergo lumbar puncture procedure~9. Unable to participate in electroencephalography (EEG) protocol due to hearing impairment or inability to tolerate EEG cap or headphones~10. Uncontrolled or unstable chronic disease~11. Kidney impairment requiring dialysis; history of renal transplant~12. Needs continuous direct medical care and nursing supervision.~13. Family history of short QT syndrome or long QT syndrome~14. Clinically significant cardiac involvement~15. History of cancer. Exceptions: localized cutaneous basal or squamous cell carcinoma in the last 5 years, low-grade localized prostate/cervical cancers, or previous localized prostate/cervical cancers that have a low likelihood of recurrence~16. Is not suited for study participation in the clinical judgment of the investigator~Additional inclusion and exclusion criteria apply, per protocol.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CY6463 (Type: EXPERIMENTAL): CY6463 once daily (QD) for approximately 87 sequential days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo QD for approximately 87 sequential days.

Based on this trial design, predict the completion outcome and termination type (if applicable).